Aging Population And Minimally Invasive Advances Will Fuel Outpatient Demand

Key Takeaways

• Accelerated migration of higher-acuity procedures and advanced operational efficiencies could substantially elevate long-term revenue growth and profitability beyond current expectations.
  
• Strategic investments in automation, portfolio optimization, and high-quality physician recruitment are poised to create lasting competitive advantages and superior net margin expansion.
  
• Heavy debt, acquisition risks, cost pressures, and industry consolidation threaten profitability, margin expansion, and the sustainability of Surgery Partners' growth strategy.

Catalysts

Owns and operates a network of surgical facilities and ancillary services in the United States.

• Analysts broadly agree that regulatory changes such as CMS expansion of ASC procedure lists and phasing out the inpatient-only list will unlock new high-acuity, higher-reimbursement procedures for Surgery Partners, but this may dramatically understate the pace and magnitude of case migration as rapid advances in minimally invasive techniques and technology could accelerate the eligibility of procedures far ahead of forecasts, significantly lifting Surgery Partners' long-term revenue and EBITDA trajectories.
  
• While analyst consensus highlights strong organic growth from physician recruitment and new de novo facility openings, these views are conservative: the compounding effect of high-quality orthopedic-focused recruitment, combined with the ramp-up of new, purpose-built higher-acuity ASCs, could structurally reset revenue per case upwards and enable sustained, double-digit total revenue growth and robust net margin expansion for multiple years.
  
• The demographic tailwind of a growing and aging U.S. population with rising chronic disease prevalence sits at an inflection point, driving an unprecedented, durable increase in procedural volumes that will materially outpace industry estimates and translate into multi-year topline acceleration for Surgery Partners.
  
• Unique operational leverage from portfolio optimization-including opportunistic divestitures, health system joint ventures, and conversion of lower-value service lines into higher-acuity platforms-could expedite deleveraging and free cash flow growth, resulting in faster-than-expected improvement in net margins and liquidity.
  
• Transformational investments in revenue cycle automation, AI-driven case scheduling, and end-to-end supply chain optimization will yield cash conversion rates and margin improvements that structurally differentiate Surgery Partners, creating a sustainable advantage and amplifying long-term earnings growth relative to peers.

Surgery Partners Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more optimistic perspective on Surgery Partners compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• The bullish analysts are assuming Surgery Partners's revenue will grow by 7.3% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from -2.3% today to 3.6% in 3 years time.
• The bullish analysts expect earnings to reach $147.8 million (and earnings per share of $1.11) by about June 2029, up from -$76.1 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $-72.5 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 28.5x on those 2029 earnings, up from -28.2x today. This future PE is greater than the current PE for the US Healthcare industry at 25.1x.
• The bullish analysts expect the number of shares outstanding to grow by 1.77% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 9.5%, as per the Simply Wall St company report.

Risks

• Rising interest rates have increased Surgery Partners' effective corporate debt rate to approximately 7.4 percent, which led to a $23 million increase in interest payments in the second quarter alone; ongoing elevated debt servicing costs could erode net margins and constrain future earnings growth.
  
• The company's heavily acquisition-driven growth strategy, with $2.2 billion in outstanding corporate debt and leverage targets still above 4 times EBITDA, exposes it to refinancing risk, higher interest expenses, and potential downgrades in credit ratings, directly threatening profitability and the ability to self-fund growth without external capital.
  
• Industry consolidation among hospitals and large health systems may enable those entities to negotiate more aggressively against independent surgery centers, putting pressure on Surgery Partners' reimbursement rates and volumes, thereby impacting revenue growth and earnings over the long term.
  
• Inflationary pressures on labor and medical supply costs risk outpacing Surgery Partners' ability to negotiate higher reimbursements, especially given commercial rate growth was only 1.6 percent in the quarter, setting up a scenario where operating leverage contracts and profit margins are squeezed.
  
• Execution risk around integrating acquired or de novo facilities, which often have lengthy ramps to profitability and frequently involve unconsolidated structures, raises the risk of inefficiencies, higher operating costs, and missed earnings targets if new facilities do not reach expected scale or margin expansion.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Surgery Partners is $23.49, which represents up to two standard deviations above the consensus price target of $17.95. This valuation is based on what can be assumed as the expectations of Surgery Partners's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $24.0, and the most bearish reporting a price target of just $14.0.
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $4.1 billion, earnings will come to $147.8 million, and it would be trading on a PE ratio of 28.5x, assuming you use a discount rate of 9.5%.
• Given the current share price of $16.56, the analyst price target of $23.49 is 29.5% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.